Co-Prescribing Abilify and Lexapro for Depression
Yes, Abilify (aripiprazole) can be safely co-prescribed with Lexapro (escitalopram) for treatment-resistant depression, with no dosage adjustment required for either medication when used together. 1
FDA-Approved Drug Interaction Profile
The FDA label for Abilify explicitly states that no dosage adjustment is necessary for escitalopram when coadministered with aripiprazole 1. This is because escitalopram is metabolized primarily by CYP2C19, and aripiprazole does not significantly affect this enzyme pathway 1. The combination has been extensively studied and is considered pharmacologically compatible.
Clinical Evidence for Combination Therapy
Efficacy Data
Aripiprazole augmentation of escitalopram demonstrates robust clinical efficacy for treatment-resistant depression:
- In a large randomized controlled trial (N=1,147), adjunctive aripiprazole achieved 36.8% remission rates versus 18.9% with placebo (P<0.001), representing a two-fold improvement 2
- Mean MADRS score improvements were significantly greater with combination therapy (-10.1 points) compared to antidepressant alone (-6.4 points; P<0.001) 2
- An open-label study specifically examining escitalopram plus aripiprazole showed a 62.5% response rate and 50% remission rate in major depressive disorder with psychotic features 3
Cognitive Benefits
The combination may offer earlier cognitive improvements compared to escitalopram monotherapy:
- Executive function improvements occurred earlier with combination therapy, particularly in Wisconsin Card Sorting Test perseverative errors 4
- Continuous attention domains showed more rapid enhancement with adjunctive aripiprazole 4
- Quality of life improvements were predicted by symptom reduction and functional gains, with the combination explaining 67-68% of variance in physical and psychological quality of life domains 5
Recommended Dosing Strategy
Starting Doses
Begin with low-dose aripiprazole augmentation:
- Escitalopram: 10-20 mg daily (standard antidepressant dosing) 6, 2
- Aripiprazole: Start at 2-5 mg daily for augmentation 7
Dose Optimization
Meta-analysis evidence suggests optimal efficacy occurs at lower doses than traditionally prescribed:
- Maximum efficacy appears between 2 mg (OR=1.46) and 5 mg (OR=1.93) daily 7
- Doses above 5 mg show no additional efficacy benefit but may increase adverse effects 7
- The FDA-approved range is 2-20 mg daily, but starting at 2-5 mg optimizes the benefit-to-harm ratio 7
Dose Adjustments for Drug Interactions
Important: If the patient is taking strong CYP2D6 or CYP3A4 inhibitors, reduce aripiprazole dose:
- Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine): Reduce aripiprazole dose by 50% 1
- Strong CYP3A4 inhibitors (itraconazole, clarithromycin): Reduce aripiprazole dose by 50% 1
- Strong CYP3A4 inducers (carbamazepine, rifampin): Double the aripiprazole dose 1
Monitoring Parameters
Baseline Assessment
Before initiating combination therapy, evaluate:
- Cardiovascular status: Both medications can prolong QT interval, though escitalopram has lower risk than citalopram 8, 6
- Blood pressure: Aripiprazole has alpha1-adrenergic antagonism that can enhance hypotensive effects 1
- Metabolic parameters: Weight, BMI, fasting glucose, lipid panel 1
- Movement disorder history: Baseline extrapyramidal symptoms assessment 3
Ongoing Monitoring
During treatment, monitor for:
- Akathisia: Occurs in up to 62.5% of patients on combination therapy, but typically resolves with dose reduction or propranolol 10-30 mg TID 3
- Orthostatic hypotension: Particularly when combined with antihypertensives 1
- Sedation: Monitor especially in first 2-4 weeks 1
- Weight and metabolic changes: Assess at weeks 4,8, and 12, then quarterly 1
- Extrapyramidal symptoms: Use Simpson Angus Scale and Barnes Akathisia Scale 3
Anxiety-Specific Considerations
Patients with anxious depression (GAD-7 ≥10) require closer monitoring:
- Higher incidence of nervousness and agitation side effects with escitalopram in first 2 weeks 9
- Start escitalopram at 5 mg daily as a "test dose" before increasing to therapeutic range 6
- Monitor anxiety symptoms closely at weeks 2 and 4 9
- Consider adding aripiprazole earlier if anxiety worsens on escitalopram alone 9
Safety Profile and Common Pitfalls
Most Frequent Adverse Effects
Central nervous system effects predominate:
- Drowsiness and nervousness are most common and most severe 9
- Akathisia develops in approximately 60% but is manageable with dose adjustment or propranolol 3
- Discontinuation rates due to adverse events remain low (6.2% with aripiprazole vs 1.7% placebo) 2
Critical Safety Warnings
Avoid this combination in patients with:
- Long QT syndrome: Escitalopram can prolong QT interval, particularly at doses >20 mg daily 6
- Concomitant QT-prolonging medications: Risk of torsades de pointes increases 8, 6
- Uncontrolled hypertension or hypotension: Aripiprazole's alpha1-antagonism can exacerbate blood pressure instability 1
Serotonin Syndrome Risk
While escitalopram is serotonergic, aripiprazole is not, reducing serotonin syndrome risk:
- The combination does not increase serotonin syndrome risk beyond escitalopram monotherapy 6
- However, avoid adding other serotonergic agents (tramadol, triptans, other SSRIs/SNRIs) 6
- Monitor for tremor, hyperreflexia, diaphoresis, and autonomic instability if multiple serotonergic drugs are necessary 6
Treatment Duration and Discontinuation
For first-episode major depression:
- Continue combination therapy for at least 4-6 months after remission 10
- Patients with recurrent depression may require prolonged or indefinite treatment 10
When discontinuing:
- Taper escitalopram gradually over 2-4 weeks to avoid discontinuation syndrome (dizziness, paresthesias, anxiety) 6
- Aripiprazole can be discontinued more abruptly due to long half-life, but gradual taper over 1-2 weeks is preferred 11
Special Populations
Older adults (>60 years):
- Escitalopram is preferred over other SSRIs due to favorable side effect profile 10
- Maximum escitalopram dose: 10 mg daily in elderly patients 8
- Start aripiprazole at 2 mg daily and increase cautiously 7
- Monitor more frequently for orthostatic hypotension and falls 1
Patients with comorbid alcohol dependence: